Fig. 6: Reducing AR strength diminishes the beneficial effect of PV axon HFS.

a Representative traces of IPSCs evoked by long-lasting trains of optic HFS before (top) and 20 min after 200 μM EGTA-AM (bottom) application in the bath. Group data of the total charge (b), AR charge (c), basal current (d) of evoked IPSCs before and after the application of 200 μM EGTA-AM (n = 6 neurons from 4 mice). For (b) (P = 0.0149) and (c) (P = 0.0258), paired t-test, two-sided. For (d) (P = 0.0053), two-way ANOVA without adjustments. e Left, schematic of bilateral virus injections and bilateral cannula implantation for drug administration. Right, a representative image (n = 4 mice) showing the position of the two cannulas above the STN. Scale bar, 500 μm. f Representative changes in locomotion velocity in response to optic stimulation of PV axons from GPe at 130 or 20 Hz before and 20 min after bilateral EGTA-AM (500 μmol; i.e., 0.5 μl with a concentration of 1 mM) administration to the STN. g, h Group data comparing the effects of optic stimulation on locomotion velocity before and after vehicle (n = 7 mice) and EGTA-AM administration (n = 7 mice). For (g) 130 Hz Ctrl: Pre vs. Stim (P = 0.0156), Vehicle: Pre vs. Stim (P = 0.0156), Wilcoxon matched-pairs signed rank test, two-sided. 20 Hz Ctrl: Pre vs. Stim (P = 0.4688), Wilcoxon matched-pairs signed rank test, two-sided; Vehicle: Pre vs. Stim (P = 0.1831), paired t-test, two-sided. For h, 130 Hz Ctrl: Pre vs. Stim (P = 0.0040), EGTA-AM: Pre vs. Stim (P = 0.0178); 20 Hz Ctrl: Pre vs. Stim (P = 0.2051), EGTA-AM: Pre vs. Stim (P = 0.2485), paired t-test, two-sided. Data are represented as mean ± SEM. NS, not significant; *P < 0.05, **P < 0.01. Source data are provided as a Source Data file.